Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Mar;69(3):749-765.
doi: 10.1007/s10620-023-08220-9. Epub 2024 Jan 13.

IBD-PODCAST Spain: A Close Look at Current Daily Clinical Practice in IBD Management

P Vega  1 , J M Huguet  2 , E Gómez  3 , S Rubio  4 , P Suarez  5 , M I Vera  6 , J M Paredes  7 , A Hernández-Camba  8 , R Plaza  9 , M Mañosa  10   11 , R Pajares  12 , B Sicilia  13 , L Madero  14 , S Kolterer  15 , C Leitner  15 , T Heatta-Speicher  15 , N Michelena  15 , R Santos de Lamadrid  15 , A Dignass  16 , F Gomollón  17
Affiliations
Multicenter Study

IBD-PODCAST Spain: A Close Look at Current Daily Clinical Practice in IBD Management

P Vega et al. Dig Dis Sci. 2024 Mar.

Abstract

Background: Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) that contributes in part to irreversible bowel damage and long-term complications, reduced quality of life, invalidity, and economic burden. Suboptimal control of IBD is associated with higher healthcare resource utilization (HCRU), impaired quality of life (QoL), and reduced work productivity.

Aims: The IBD-PODCAST study aimed to assess the proportion of IBD patients with suboptimal control and its associated impact.

Methods: IBD-PODCAST is a cross-sectional, multicenter study that aimed to characterize the CD and UC population with optimal or suboptimal control according to the STRIDE-II criteria and patient- and physician-reported measures. Here we present the results of the Spanish cohort (n = 396).

Results: A total of 104/196 (53.1%) CD and 83/200 (41.5%) UC patients were found to have suboptimal disease control. Long-term treatment targets according to STRIDE-II were applied in 172 (87.8%) CD and 181 (90.5%) UC patients. 125 of 172 (72.7%) CD and 74 of 181 (40.9%) UC patients were currently treated with targeted immunomodulators. Patients with CD and UC and suboptimal disease control showed impaired QoL, higher HCRU and direct costs, and also loss of work productivity compared to those with optimal control.

Conclusion: Despite a high rate of targeted immunomodulator therapy, a substantial proportion of IBD patients show suboptimal disease control according to the STRIDE II criteria. Those patients with suboptimal disease control exhibit impaired QoL, less work productivity, and higher HCRU, suggesting that there is considerable need for better treatment approaches in IBD.

Keywords: Crohn’s disease; Inflammatory bowel diseases; STRIDE II recommendations; Treat to target strategy; Ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Pablo Vega has received honoraria as speaker from Janssen, Abbvie, Takeda and MSD; and participated in advisory panels for Takeda and Abbvie. JM Huguet reports educational activities, research projects, scientific meetings, advisory boards sponsored by MSD, Ferring, Abbvie, Janssen, Sandoz, Kern Pharma, Faes Farma, and Takeda. Elena Gómez has received honoraria as speaker from Janssen, Abbvie, Takeda, Ferring, Falk, Adacyte Therapeutics and Casen Recordati. JM Paredes reports educational activities, research projects, scientific meetings or advisory boards sponsored by MSD, Ferring, Abbvie, Janssen, Kern Pharma and Takeda. Rocío Plaza has received honoraria as speaker from Janssen, Abbvie and Takeda and travel expenses from Ferring, Dr.FALK, Pfizer and Tillots Pharma. “Saioa Rubio reports educational activities and has received honoraria as speaker from Abbvie, Ferring, Jassen, Takeda and Tillots. Alejandro Hernández-Camba has served as a speaker or has received research funding from AbbVie, Janssen, Pfizer, Galapagos, Faes-Farma, Ferring, Kern Pharama, Takeda, Tillots. Patricia Suarez has received honoraria as speaker from Abbvie, Janssen, Gebro pharma, Takeda, Abbott, Ferring, Tillotts y Falk pharma. Isabel Vera has received honoraria as speaker, consultant and advisory member for MSD, Abbvie, Pfizer, Ferring, Shire Pharmaceuticals, Takeda, Tillots, Janssen Pharmaceuticals and Galapagos. Ramón Pajares has received honoraria as speaker from Takeda and travel expenses from Takeda and Janssen. Míriam Mañosa has served as a speaker, consultant and advisory member for or has received research funding from AbbVie, Janssen, MSD, Pfizer, Galapagos, Faes-Farma, Takeda, Tillots. Beatriz Sicilia reports educational activities, investigational activities and scientific meetings or advisory boards sponsored by Abbvie, FAES, Chiesi, Dr. Falk, MSD, Tillots Pharma, Khern Pharma, Janssen, Pfizer y Takeda. Lucía Madero has received honoraria as speaker from Abbvie. Stefanie Kolterer was employee of AbbVie and is currently employee at GSK and may own stock/options. Tobias Heatta-Speicher, Claudia Leitner, Naiara Michelena, Regina Santos de Lamadrid are employees of AbbVie and may own stock/options. A. Dignass has received fees for participation in clinical trials and for review activities, such as data monitoring boards, statistical analysis and endpoint committees from Abivax, AbbVie, Arena, Celgene/Bristol Myers Squibb, Falk, Gilead, Janssen and Pfizer; consultancy fees from AbbVie, Amgen, Biogen, Boehringer-Ingelheim, Celgene/Bristol Myers Squibb, Celltrion, Falk, Ferring, Fresenius Kabi, Galapagos, Gilead, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Roche/Genentech, Sandoz/Hexal, Takeda, Tillotts and Vifor; and payment for lectures including service on speaker bureaus from AbbVie, Amgen, Biogen, Celltrion, Falk Foundation, Ferring, Gilead/Galapagos, Janssen, Lilly, MSD, Pharmacosmos, Pfizer, Takeda, Tillotts and Vifor. Fernando Gomollón has received honoraria as speaker from Janssen, AbbVie, Takeda and MSD; and participated in advisory panels for Faes-Farma and AbbVie.

Figures

Fig. 1
Fig. 1
Proportion of patients with suboptimal and optimal control based on red flags according to STRIDE II
Fig. 2
Fig. 2
Escalation of current TIM maintenance therapy of patients with suboptimal disease control in CD and UC. Already escalated: includes escalated TIM therapy only
Fig. 3
Fig. 3
a Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Score in suboptimal control vs optimal control patients. Means and standard deviation were calculated based on total number (N) of patients defined as SOC by red flags. b Short Inflammatory Bowel Disease Questionnaire Sub Items (SIBDQ) Score in suboptimal vs optimal control of all patients. Means and standard deviation were calculated based on total number (N) of patients defined as suboptimal control by red flags
Fig. 4
Fig. 4
Work productivity assessment using the Work Productivity and Activity Impairment (WPAI) questionnaire in suboptimal vs optimal control patients. Means and standard deviation were calculated based on total number (N) of patients defined as inadequately controlled by red flags. The differences in mean (SD) scores for absenteeism, presenteeism and working productivity loss in CD and UC patients were calculated based on the total number (N) of patients working at index date that completed this question in the questionnaire. Means and standard deviation for activity impairment were calculated based on the total number (N) of patients that completed this question in the questionnaire
Fig. 5
Fig. 5
Three-way Venn diagram of not optimal disease control based on patient view, HCP view, and based on red flags according to STRIDE II. A Crohn’s disease (N = 119). B Ulcerative colitis (N = 95). Percentages (%) were calculated based on the total number (N) of patients defined as suboptimal control by either clinician, patient, or red flags
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Sairenji T, Collins KL, Evans DV. An Update on Inflammatory Bowel Disease. Prim Care. 2017;44(4):673–692. doi: 10.1016/j.pop.2017.07.010. - DOI - PubMed
    1. Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389(10080):1741–1755. doi: 10.1016/S0140-6736(16)31711-1. - DOI - PubMed
    1. Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2011;7(4):235–241. - PMC - PubMed
    1. Harbord M, Annese V, Vavricka SR, et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10(3):239–254. doi: 10.1093/ecco-jcc/jjv213. - DOI - PMC - PubMed
    1. Hedin CRH, Vavricka SR, Stagg AJ, et al. The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. J Crohns Colitis. 2019;13(5):541–554. doi: 10.1093/ecco-jcc/jjy191. - DOI - PubMed

Publication types

MeSH terms

Substances